Zelboraf (Vemurafenib) and Cotellic (Cobimetinib) Treatment Regimen

Cutaneous melanoma is biologically heterogeneous ; approximately 40–50%of cases carry a BRAF V600 mutation. In this group, vemurafenib (BRAF inhibitor) + cobimetinib (MEK inhibitor) produces MAPK/ERK pathway two-level blockade , achieving rapid tumor shrinkage and high objective response rates. It has particular clinical value with high tumor burden, symptomatic disease and a need for rapid response . Before treatment, a BRAF V600 mutation must be confirmed using an approved test as required.

📌 Drug Profiles and Indications

• Vemurafenib: Selective BRAF V600 inhibitor (oral). Our information page
• Cobimetinib: MEK1/2 inhibitor (oral). Our information page
• Indication: Unresectable or metastatic, BRAF V600E/K-positive cutaneous melanoma.
• Clinical goal: Rapid burden control, high ORR, improved PFS/OS ; immunotherapy sequencing is individualized to disease kinetics.

⚙️ How Does It Work? (Mechanism)

• Dual blockade: Vemurafenib inhibits BRAF and cobimetinib inhibits MEK1/2, reducing ERK phosphorylation → suppressed proliferation/invasion signaling.
• Delaying resistance: MEK inhibition limits ‘paradoxical activation’ and bypass pathways (NRAS, MEK gains, etc.) occurring with BRAF blockade alone.
• Clinical implication: Compared with a BRAF inhibitor alone, the combination improves ORR, PFS and OS(coBRIM).

📊 Guideline Position & Evidence Summary

• Guideline: BRAF V600-positive stage IV/unresectable melanoma: a recommended BRAF/MEK doublet; choice versus IO (PD-1 ± CTLA-4) depends on clinical context.
• coBRIM (Phase 3): Vemurafenib + cobimetinib vs vemurafenib + placebo.
  • Primary: Significantly superior PFS.
  • Secondary: Improved ORR and OS.
  • Safety: Phototoxicity/rash (vemurafenib); CPK↑ and serous retinopathy (cobimetinib).

Long term: PFS/OS benefits persist; toxicity has a manageable profile.

🧪 Dosing and Administration Schedule

Example dose reductions —Vemurafenib: 960→720→480 mg BID; Cobimetinib: 60→40→20 mg QD (21/28 schedule unchanged).

• QTc ≥500 ms / arrhythmia: Vemurafenib interruption/discontinuation, correct electrolytes, review QT-prolonging drugs; <500 ms may allow consideration of restarting at a lower dose.
• Serous retinopathy / RVO (cobimetinib): According to severity, interrupt / permanently discontinue (usually discontinue with RVO).
• G≥3 rash/phototoxicity: Implicated drug(s) withhold → resume at reduced dose at ≤G1.
• CPK↑/symptomatic myositis: Cobimetinib interruption/reduction; review concomitant drugs (including statins).

⚠️ Precautions During Use

• Sun protection: Broad-spectrum SPF ≥30, UVA/UVB protection, covering clothing; avoid tanning beds.
• ECG + electrolytes (K/Mg/Ca): Baseline, month 1, and as clinically needed.
• Eye symptoms (blurred vision, photopsia, metamorphopsia): urgent ophthalmology.
• Muscle pain/weakness: Monitor CPK; if elevated, interrupt cobimetinib and restart gradually.
• LFTs/blood counts: At cycle start and when symptoms occur.
• Secondary cutaneous malignancies (vemurafenib): Regular dermatological checks; excision + multidisciplinary decision if lesions appear.
• Pregnancy/Breastfeeding: Contraindicated/not recommended; effective contraception required.

💳 SGK Reimbursement (Türkiye)

• Framework: Both drugs are licensed in Türkiye. Under EK-4/A records, the indication of BRAF V600-positive metastatic/unresectable cutaneous melanoma may qualify for reimbursement. Relevant wording: ‘In relapsed/metastatic melanoma patients with no previous RAF pathway inhibitor, ECOG 0–1, a BRAF V600 mutation, progression after local treatment, and inability to repeat local treatments, treatment until progression in combination with vemurafenib is reimbursed by SGK.”
• Practical report: The health board report must clearly document BRAF V600 (approved test) results, ECOG, regimen, and prior RAF/MEK use.
• Warning: SUT/EK-4/A and Medula announcements are periodically updated; confirm current lists with pharmacy/SGK staff before applying.
• Price: Zelboraf 240 mg tablets: 27,295.25 TL; Cotellic 20 mg tablets: 90,833.51 TL. (Center practice and dates may vary.)

🔄 Selected Drug Interactions

• Vemurafenib: CYP1A2 inhibitor, CYP3A4 inducer → caution with narrow-therapeutic-range 1A2/3A4 substrates; QT-prolonging drugs: avoid or monitor closely.
• Cobimetinib: CYP3A substrate → strong CYP3A inhibitors/inducers (ketoconazole, clarithromycin / rifampicin, carbamazepine, phenytoin): avoid or adjust dose/monitoring.
• Concurrent ipilimumab is not recommended (increased hepatotoxicity); sequential approaches are preferred.

🛡️ Side Effects — Summary & Management

Tip: Photosensitivity may increase in summer; intensify protection and monitoring.

✅ Follow-Up and Monitoring

• ECG + electrolytes (K/Mg/Ca): Baseline, month 1, and as indicated.
• Eye examination: Baseline + with symptoms; urgent if serous retinopathy/RVO suspected.
• CK/CPK: Baseline and each cycle start; increase frequency with myalgia/weakness.
• LVEF (echocardiography): Baseline and every 8–12 weeks with cobimetinib (according to clinical need).
• LFTs/blood counts: At cycle starts and with symptoms.
• Skin examination: Every 4–8 weeks; watch for new lesions.
• Imaging: Disease assessment every 8–12 weeks (RECIST-compliant report).

🧩 Special Situations (Practical Notes)

• Brain metastases: May be combined with locoregional methods (SRS/RT); targeted therapy may be favored with symptomatic disease needing rapid burden control; IO is a strong alternative when stable.
• Hepatic/renal impairment: Usually standard doses in mild-to-moderate impairment; close toxicity monitoring and modification in severe impairment.
• Older/comorbid patients: More frequent monitoring for cardiac (QT/LVEF), muscular (CPK), and visual AEs; closely review concomitant medications.
• Perioperative period: Team decision about temporary interruption before major surgery and wound healing.
• Pregnancy/Breastfeeding: Contraindicated/not recommended; multidisciplinary oncology–gynecology assessment for planned pregnancy.

📚 References

1. Larkin J, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014.
2. Ascierto PA, et al. Updated coBRIM efficacy results. Lancet Oncology 2016.
3. Cotellic® (cobimetinib) US Prescribing Information (dose modifications, CPK/LVEF/retinopathy, CYP3A).
4. Zelboraf® (vemurafenib) US Prescribing Information (QT prolongation, phototoxicity, secondary cutaneous malignancies, interactions).
5. NCCN Guidelines® Melanoma (2025).
6. SGK EK-4/A and related announcements (Zelboraf® and Cotellic® records; Medula/SUT updates).